Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Jun 23, 2023 (3 years ago)

Tizanidine Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Failed Dissolution Specifications: this repackaged product was recalled by the manufacturer, Dr. Reddy's Laboratories, Inc., due to out of specification results for dissolution.

Cause type: Dissolution failure

The tablet or capsule did not dissolve within specification. Dissolution controls how much drug the body absorbs; a failure can change the effective dose. All dissolution failure recalls.

What was recalled

Tizanidine Tablets, USP, 4 mg, 100 Tablets (10 tablets x 10 unit dose blister packs) per carton, Rx Only, Packaged and Distributed by: American Health Packaging, Columbus, Ohio 43217, NDC 68084-645-01 (carton), barcode (01) 003 68084 645 11 2.

Affected NDC 68084-0645-01

Compare with the code on your package — it is the most precise check available.

Drug: Tizanidine

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Tizanidine
NDC 68084-0645
HYDROCHLORIDE 4 mg/1 Tablet
Oral
American Health Packaging Rx
Recalling firm
Amerisource Health Services LLC
NDC code
68084-645-01
Origin
OH, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0892-2023 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Tizanidine recalls

See all
Class II · Moderate risk

Tizanidine Tablets

Presence of Foreign tablets/capsules - identified as tizanidine 2 mg tablets.

Completed Particulate / foreign matter Dr. Reddy's Laboratories, Inc. NDC 55111-180-15 D-0223-2024
Class II · Moderate risk

Tizanidine Tablets USP

Failed dissolution specification: Out of specification results observed in 24-month long term stability testing.

Ongoing Dissolution failure Dr Reddy's Laboratories Limited NDC 55111-180-10 D-0923-2023
Class II · Moderate risk

Tizanidine HCl Tablets

Failed Tablet/Capsule Specification: Some tablets are shaved

Terminated Failed specification Dr. Reddy's Laboratories, Inc. NDC 55111-180-15 D-0750-2021
Class II · Moderate risk

Tizanidine Tablets

Failed Dissolution Specifications; Out of Specification (low) results were obtained.

Terminated Dissolution failure Ascend Laboratories LLC D-0173-2021

Other recalls by Amerisource Health Services LLC

All 2023 recalls
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Amerisource Health Services LLC D-0537-2026
Class III · Low risk

Primidone Tablets

Cross contamination with other products: API contaminated with trace amounts of Acemetacin API.

Ongoing Cross-contamination Amerisource Health Services LLC D-0536-2026
Class II · Moderate risk

Oxycodone Hydrochloride Tablets

Defective container: card seal defects (weak/non-existent seals), leading to the tablets falling out of their cavities.

Ongoing Packaging defect Amerisource Health Services LLC NDC 68084-354-01 D-0338-2026